{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:50:47Z","timestamp":1777884647447,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.euo.2025.02.015","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:26:06Z","timestamp":1747153566000},"page":"240-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer"],"prefix":"10.1016","volume":"9","author":[{"given":"Nobuaki","family":"Matsubara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Petrylak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Ratta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Korbenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rustem","family":"Gafanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Mourey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilman","family":"Todenh\u00f6fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Gurney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andries M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Zalewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria De","family":"Santis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winald","family":"Gerritsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell K.","family":"Pachynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd L.","family":"Saretsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer R.","family":"Ghate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Schloss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.02.015_b0005","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3109\/0284186X.2012.760848","article-title":"Health-related quality of life in prostate cancer","volume":"52","author":"Torvinen","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.euo.2025.02.015_b0010","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12904-018-0381-6","article-title":"Quality of life in men with metastatic prostate cancer in their final years before death\u2014a retrospective analysis of prospective data","volume":"17","author":"Holm","year":"2018","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.euo.2025.02.015_b0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.2022.40.28_suppl.205","article-title":"Health-related quality of life among metastatic prostate cancer survivors: comparisons to survivors originally diagnosed with localized disease and men without a cancer history in the United States","volume":"40","author":"Zheng","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.015_b0020","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO clinical practice guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.02.015_b0025","first-page":"1288","article-title":"NCCN Guidelines\u00ae insights: prostate cancer, version 1.2023","volume":"20","author":"Schaeffer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2025.02.015_b0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.eururo.2022.02.023","article-title":"Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort B study","volume":"82","author":"Yu","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.015_b0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2023.41.6_suppl.19","article-title":"Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): randomized, double-blind, phase 3 KEYNOTE-921 study","volume":"41","author":"Petrylak","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.015_b0040","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0090-4295(97)00459-7","article-title":"Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument","volume":"50","author":"Esper","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.02.015_b0045","doi-asserted-by":"crossref","unstructured":"EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199\u2013208.","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"10.1016\/j.euo.2025.02.015_b0050","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00019053-200725050-00002","article-title":"Health utilities using the EQ-5D in studies of cancer","volume":"25","author":"Pickard","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.euo.2025.02.015_b0055","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.euo.2025.02.015_b0060","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.euo.2025.02.015_b0065","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1016\/j.ejca.2013.07.144","article-title":"Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy","volume":"49","author":"Harland","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2025.02.015_b0070","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/annonc\/mdu510","article-title":"Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial","volume":"26","author":"Cella","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.02.015_b0075","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.02.015_b0080","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(20)30449-6","article-title":"Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study","volume":"21","author":"Fizazi","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.02.015_b0085","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(22)00017-1","volume":"23","author":"Thiery-Vuillemin","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.02.015_b0090","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.02.015_b0095","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1524-4733.2008.00409.x","article-title":"Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy\u2013Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer","volume":"12","author":"Cella","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.euo.2025.02.015_b0100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.euo.2025.02.015_b0105","first-page":"134","article-title":"Longitudinal data analysis of continuous and discrete responses for pre-post designs","volume":"62","author":"Liang","year":"2000","journal-title":"Sankhy\u0101 Ser B"},{"key":"10.1016\/j.euo.2025.02.015_b0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1200\/JCO.2023.41.6_suppl.131","article-title":"Patient-reported outcomes (PROs) in KEYLYNK-010: pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Mehra","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.015_b0115","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1200\/JCO.2005.04.8207","article-title":"Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone","volume":"24","author":"Berry","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.015_b0120","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:32:50Z","timestamp":1777602770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125000501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2588931125000501"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.02.015","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates and The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}